Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO (ivosidenib tablets) in the Treatment of IDH1-mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)  Yahoo Finance

Read this article:

Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO (ivosidenib tablets) in the Treatment of IDH1-mutated Relapsed or Refractory...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh